Announced that the amount of “antibody” increased with the vaccine under development such as Pfizer and announced
Early clinical trials of a new coronavirus vaccine being developed by an American pharmaceutical company confirmed that the amount of “antibodies” that play a role in immunity increased after vaccination. Phased research results have been announced.
The early-stage results of clinical trials of a new coronavirus vaccine developed by American pharmaceutical giant "Pfizer" and German "Biontech" were published in the British science magazine "Nature" on the 12th.
The test was conducted in 45 people aged 18 to 55 years, 21 days after vaccination, antibodies to the new coronavirus were detected in the blood of all vaccinated people, and the function of the virus was weakened. It was also confirmed that the amount of "neutralizing antibody" increased.
The amount of "neutralizing antibodies" was 1.9 to 4.6 times higher than the amount detected in the blood of people who recovered after being infected with the new coronavirus.
On the other hand, more than half of the vaccinated people reported physical disorders such as headaches, but no serious health effects were reported.
If the development of Pfizer and Biontech vaccines is successful, the U.S. government has agreed to supply at least 100 million doses, and the Japanese government is expected to receive 60 million doses by the end of June next year. I agree.
The vaccine has been in the third stage of clinical trials, which is the final stage of development since last month, and Pfizer is aiming for approval in October at the earliest.